These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 672730)

  • 21. Labetalol: a review of its pharmacology, pharmacokinetics, clinical uses and adverse effects.
    MacCarthy EP; Bloomfield SS
    Pharmacotherapy; 1983; 3(4):193-219. PubMed ID: 6310529
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A controlled trial of labetalol (Trandate), propranolol and placebo in the management of mild to moderate hypertension.
    Pugsley DJ; Nassim M; Armstrong BK; Beilin L
    Br J Clin Pharmacol; 1979 Jan; 7(1):63-8. PubMed ID: 367410
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Step II treatment with labetalol for essential hypertension.
    Bloomfield SS; Lucas CP; Gantt CL; Poland MP; Medakovic M
    Am J Med; 1983 Oct; 75(4A):81-6. PubMed ID: 6356902
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Labetalol: an alpha- and beta-adrenoceptor blocking drug.
    Michelson EL; Frishman WH
    Ann Intern Med; 1983 Oct; 99(4):553-5. PubMed ID: 6137987
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monotherapy with labetalol for hypertensive patients with normal and impaired renal function.
    Thompson FD; Joekes AM; Hussein MM
    Br J Clin Pharmacol; 1979; 8(Suppl 2):129S-133S. PubMed ID: 526392
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A multicentre study of labetalol in hypertension. New Zealand Hypertension Study Group.
    N Z Med J; 1981 Apr; 93(681):215-8. PubMed ID: 7017511
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The treatment of hypertension by labetalol--a new alpha- and beta-adrenoreceptor blocking agent.
    Stern N; Teicher A; Rosenthal T
    Clin Cardiol; 1982 Feb; 5(2):125-30. PubMed ID: 7039899
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of hypertension in the elderly with labetalol.
    Eisalo A; Virta P
    Acta Med Scand Suppl; 1982; 665():129-33. PubMed ID: 6961759
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Labetalol and propranolol in mild hypertensives: comparison of blood pressure and plasma volume effects.
    Hunyor SN; Bauer GE; Ross M; Larkin H
    Aust N Z J Med; 1980 Apr; 10(2):162-6. PubMed ID: 6930206
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Controlled comparison of labetalol and propranolol in the management of severe hypertension.
    Pugsley DJ; Armstrong BK; Nassim MA; Beilin LJ
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):777-82. PubMed ID: 791331
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravenous labetalol in the management of severe hypertension and hypertensive emergencies.
    Cressman MD; Vidt DG; Gifford RW; Moore WS; Wilson DJ
    Am Heart J; 1984 May; 107(5 Pt 1):980-5. PubMed ID: 6720529
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative anti-hypertensive effects of labetalol and the combination of oxprenolol and phentolamine.
    Johnson BF; LaBrooy J; Munro-Faure AD
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):783-7. PubMed ID: 791332
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term treatment of hypertension with labetalol.
    Erichs M; Rothgardt NP; Andersson E
    Postgrad Med J; 1980; 56 Suppl 2():53-6. PubMed ID: 7433343
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Labetalol, a new alpha- and beta-adrenoreceptor blocking agent, in hypertension.
    Hansson L; Hänel B
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):763-4. PubMed ID: 10952
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The use of labetalol in Japan: results of multicentre clinical trials.
    Takeda T; Kaneko Y; Omae T; Yoshinaga K; Masuyama Y; Nukada T; Shigiya R
    Br J Clin Pharmacol; 1982 Jun; 13(1 Suppl):49S-57S. PubMed ID: 7046774
    [TBL] [Abstract][Full Text] [Related]  

  • 36. "Third drug" trial: comparative study of antihypertensive agents added to treatment when blood pressure remains uncontrolled by a beta blocker plus thiazide diuretic.
    McAreavey D; Ramsey LE; Latham L; McLaren AD; Lorimer AR; Reid JL; Robertson JI; Robertson MP; Weir RJ
    Br Med J (Clin Res Ed); 1984 Jan; 288(6411):106-11. PubMed ID: 6419809
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A study of labetalol, a new alpha- and beta-adrenoceptor blocking agent, in humans.
    Vas A; Gachályi B; Káldor A
    Int J Clin Pharmacol Ther Toxicol; 1982 Oct; 20(10):491-2. PubMed ID: 7141757
    [No Abstract]   [Full Text] [Related]  

  • 38. Multicenter clinical evaluation of long-term efficacy and safety of labetalol in treatment of hypertension.
    Michelson EL; Frishman WH; Lewis JE; Edwards WT; Flanigan WJ; Bloomfield SS; Johnson BF; Lucas C; Freis ED; Finnerty FA
    Am J Med; 1983 Oct; 75(4A):68-80. PubMed ID: 6356901
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alternatives to beta-blockade in therapy of hypertension with angina pectoris: role of nifedipine or of labetalol.
    Opie LH; White D; Lee J; Lubbe WF
    Br J Clin Pharmacol; 1982 Jun; 13(1 Suppl):115S-122S. PubMed ID: 7093094
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Labetalol: a review of its pharmacology and therapeutic use in hypertension.
    Brogden RN; Heel RC; Speight TM; Avery GS
    Drugs; 1978 Apr; 15(4):251-70. PubMed ID: 25757
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.